Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Ordinary Shares, $0.0001 par value
-
Shares outstanding
-
53,512,954,839
-
Total 13F shares
-
121,755
-
Share change
-
-1,287
-
Total reported value
-
$379,836
-
Price per share
-
$3.12
-
Number of holders
-
7
-
Value change
-
-$22,758
-
Number of buys
-
3
-
Number of sells
-
3
Institutional Holders of Akari Therapeutics Plc - Ordinary Shares, $0.0001 par value (AKTX) as of Q4 2023
As of 31 Dec 2023,
Akari Therapeutics Plc - Ordinary Shares, $0.0001 par value (AKTX) was held by
7 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
121,755 shares.
The largest 7 holders included
Omnia Family Wealth, LLC, Cerity Partners LLC, RENAISSANCE TECHNOLOGIES LLC, BANK OF AMERICA CORP /DE/, Truvestments Capital LLC, MORGAN STANLEY, and Tower Research Capital LLC (TRC).
This page lists
7
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.